Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21055380 | 0.91 | DGAT1 (0.36) | DGAT1NPC1MAPT | |
| SCHEMBL26690074 | 0.86 | DGAT1 (0.36) | DGAT1NPC1 | |
| SCHEMBL17919409 | 0.85 | NPC1 (0.32) | DGAT1NPC1MAPT | |
| SCHEMBL24150516 | 0.84 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL30379660 | 0.84 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL30380108 | 0.82 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL24150487 | 0.82 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL31460064 | 0.81 | DGAT1 (0.34) | DGAT1NPC1 | |
| SCHEMBL29563026 | 0.80 | NPC1 (0.32) | DGAT1NPC1MAPT | |
| SCHEMBL19950632 | 0.80 | NPC1 (0.32) | DGAT1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247990-B1 | Bicyclic fused pyridine compounds as inhibitors of TAM kinases | ARRAY BIOPHARMA INC (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2019113190-A1 | BICYCLIC FUSED PYRIDINE COMPOUNDS AS INHIBITORS OF TAM KINASES | ARRAY BIOPHARMA INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113190-A1 | BICYCLIC FUSED PYRIDINE COMPOUNDS AS INHIBITORS OF TAM KINASES | ARRAY BIOPHARMA INC. (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247990-B1 | Bicyclic fused pyridine compounds as inhibitors of TAM kinases | MAP3K1, MAP3K3, MAP3K2 | DGAT1 4739/4885NPC1 4446/4885MAPT 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.